Sopheon « Terug naar discussie overzicht

'n hart onder de riem vanaf de werkvloer

25 Posts, Pagina: 1 2 » | Laatste

Omlaag ↓

zakgeld 16 oktober 2005 11:37

Dit weekend ontmoette ik iemand die klaagde over het beleid op z'n werk. Op mijn vraag waar hij precies werkte bleek dat het M.C.R.Z. in Rotterdam. Bij mij ging meteen een lichtje op en vroeg naar hun computersysteem. Hij lichtte helemaal op en zei: fantastisch, sinds ongeveer 'n maand op 5,6 hebben we een nieuw systeem, prachtig en hij ging uitvoerig vertellen wat nu allemaal kon en hoe het werkte. Toen vroeg hij: waarom wil je dat weten? En ik met trots: Nou ik ben aandeelhouder van het bedrijf dat dat gemaakt en geleverd heeft.
Op zijn verzoek plaats ik hier een lijstje met klanten en natuurlijk mag hierop gecorrigeerd worden want ik weet niet alles zeker:
1 ACH Food '05
2 Acist Med. Gr. '05
3 Airbus Ind.
4 Amtec '03
5 Atrium '05
6 Azm '03
7 Basf '04
8 Bayer
9 Boeing Airbus
10 Bady '05
11 Cadbury Schweppes
12 Cargill
13 Celanese
14 Clariant
15 Cytec Surface Spec.
16 Domtar
17 Dow Chemical
18 DSM
19 Dupont
20 Ericsson
21 Eurest
22 Ferro Corp. '04
23 F.T.
24 Freudenberg/Vileda
25 G.E. '01
26 Glatfelter '03
27 GlaxoSmithKline
28 Great Lakes
29 Grohe
30 Hospira ,05
31 Huber Corp. '03
32 H.P.
33 Johns Mansville
34 Lockheed Martin
35 Lenzing '04
36 Lonza
37 L'oreal
38 3M
39 M.R.C.Z. '05
40 Mead Johnson & Co
41 Merck
42 Millipore Corp. '03
43 Mott's
44 Nat. Gypsum '03
45 Nautilus '05
46 Nestle
47 Pall Corp. '02
48 Parker Hannifin
49 Pennzoil
50 Pfizer '03
51 Printpack's '05
52 Revlon '03
53 Sappi Fine Paper '02
54 Sabic
55 Shell
56 Teyin Twaron '04
57 UCB '04
58 Unifi '04
59 Vodafone U.K. '01
60 Welllman '03
61 Whatman

mvg M

Bertus S 16 oktober 2005 12:08

Marijke, dit betekent natuurlijk een nieuwe a.s. aandeelhouder en enthousiaste forumbezoeker............

Bertus S.

vreemdvermogen 16 oktober 2005 14:00

Kijk aan weer een tevreden klant erbij. Moeten ze vooral door vertellen bij de andere ziekenhuizen.
Of dat lijstje klopt betwijfel ik. Er zitten ook wat oude klanten tussen. Verder kan je American Express, Berkshire Hathaway, Becton Dickinson en Bristol Meyers
(= cytec?) bijschrijven.

jan

Bertus S 16 oktober 2005 16:33

Cytec Surface Spec. komt i.p.v. UCB

UCB heeft een jaar geleden precies dát stuk, UCB Surface Spec. incl. het daar een maand daarvoor ingevoerde Accolade, verkocht aan Cytec Surface Spec.

Bertus S.

[verwijderd] 16 oktober 2005 17:25

is dit een nieuwe van H-C??

VUMC

Healthcare Solutions

--------------------------------------------------------------------------------

Sopheon's Healthcare division was formed to enhance knowledge intensive processes in hospitals. This division focuses on managing protocols, regulations and other instructions as part of the primary process, and then keeping the medical content up to date for the medical specialists. Both processes are very important for 'evidence based' medicine, as it is currently practiced. The quality and efficiency of medical and nursing actions are top priority.

Our products are the result of our experience with the processes in many hospitals and institutes, particularly three Dutch teaching hospitals (AZG, AZM, VUMC), combined with our own linguistic knowledge of documenting, writing, reading and of course ICT. For instance, QualiFlow includes a terminology component, and our own 'linguistic engine' drives Evidence Monitor.

We not only offer the software but also specialized Sopheon 'content', i.e. nursing protocols. These are written by specialists of our partners AZG, AZM and VUMC and are available in database and document format.

ron

Bertus S 16 oktober 2005 19:13

quote:
the"surfman"R schreef:
is dit een nieuwe van H-C??

VUMC

ron

Ik kende um nog niet in relatie tot H-C

Ze werken wél veel samen met het AMC (die wél met Sopheon-software werkt):

www.vumc.nl/aig/onderwijs/Candida.pdf

Denk dat Nico/Tritace hier mogelijk meer over kan zeggen.

Bertus S.

passeur 16 oktober 2005 19:50

U wilt namen....

pls-ansatz.de/imperia/md/content/wiwi...

U krijgt namen....

Groet, Arno

[verwijderd] 16 oktober 2005 20:24

quote:
passeur schreef:
U wilt namen....

pls-ansatz.de/imperia/md/content/wiwi...

U krijgt namen....

Groet, Arno

eindelijk weer die sheet waar GE in het midden prijkt
deze was ik lange tijd zoek,bedankt Arno.

ron

[verwijderd] 16 oktober 2005 21:05

hallo Bertus,weet jij over deze iets,kon het niet terugvinden.

Hospital in the Netherlands selects software to manage clinical trial operations
May 31st, 2005

Sopheon announced that Medisch Centrum Rijnmond-Zuid (MCRZ), one of the largest general hospitals in the Netherlands, has deployed Sopheon's Accolade solution to support an enhanced process for the management of clinical trials.
The software will be used by the organization's newly formed Research and Science Bureau, board of directors and medical staff as part of a major initiative aimed at growing revenues by increasing the volume of trial activity.

MCRZ has 3,200 employees. It currently completes approximately 50 clinical trials annually for leading pharmaceutical companies, for universities as coinvestigator, and for MCRZ investigator-initiated research....

ron

[verwijderd] 16 oktober 2005 21:14

www.sopheon.com/press_release.asp?rel=76

[verwijderd] 16 oktober 2005 21:19

ff uit de oude doos.(zal unilever accolade gebruiken??)

Accolade for R&D support
Anglo-Dutch company Sopheon, best known for software that aids medical personnel in diagnosis and prompts them to follow best practice, has a new product, Accolade, which has attracted much interest from those who develop products for consumer healthcare giants, Shan Kelly reports.

Information World Review Staff, Information World Review 01 Dec 2000
Companies such as Unilever and SmithKline Beecham spend fortunes developing recipes for whitening toothpaste, cold remedies and haircare products. Consumer healthcare research and development cost an estimated $186 billion last year, according to Sopheon's vice president of business development James McFarlane.

Sopheon believes Accolade, a newly launched knowledge management product, can speed up the research process and so help cut development costs dramatically.

"We are entering virgin territory. This market is enormous, yet there is virtually no software available to automate support for research and development," claims McFarlane.

Accolade was developed after oil products producer Penzoil, an existing Sopheon customer, found out that Sopheon was working with two Canadian academics, Professors Coopers and Edgett, who have developed widely accepted theories about KM in new product development.

Penzoil had been using Cooper's and Edgett's theories and was excited to hear that Sopheon believed it could create a software package based on them. Penzoil paid $200,000 to help develop Accolade, which Sopheon launched in October.

www.vnunet.com/articles/print/2083047

ron

[verwijderd] 16 oktober 2005 21:26

quote:
the"surfman"R schreef:
ff uit de oude doos.(zal unilever accolade gebruiken??)

Accolade for R&D support
Anglo-Dutch company Sopheon, best known for software that aids medical personnel in diagnosis and prompts them to follow best practice, has a new product, Accolade, which has attracted much interest from those who develop products for consumer healthcare giants, Shan Kelly reports.

Information World Review Staff, Information World Review 01 Dec 2000
Companies such as Unilever and SmithKline Beecham spend fortunes developing recipes for whitening toothpaste, cold remedies and haircare products. Consumer healthcare research and development cost an estimated $186 billion last year, according to Sopheon's vice president of business development James McFarlane.

Sopheon believes Accolade, a newly launched knowledge management product, can speed up the research process and so help cut development costs dramatically.

"We are entering virgin territory. This market is enormous, yet there is virtually no software available to automate support for research and development," claims McFarlane.

Accolade was developed after oil products producer Penzoil, an existing Sopheon customer, found out that Sopheon was working with two Canadian academics, Professors Coopers and Edgett, who have developed widely accepted theories about KM in new product development.

Penzoil had been using Cooper's and Edgett's theories and was excited to hear that Sopheon believed it could create a software package based on them. Penzoil paid $200,000 to help develop Accolade, which Sopheon launched in October.

www.vnunet.com/articles/print/2083047

ron

ook uit de oude doos (vond die klanten lijst wel aardig)

Like some 'bears' who post to this site, I make no apologies for being a cautious 'bull' and hopefully without 'boring' everybody, will summarize some facts as to why I am a bull, why I invest in Sopheon and where I believe the KM market (and hopefully Sopheon) is going, this may result in a little more than 5 lines.

You will note that I do not make comment to cash flow or profits, as I will not become engaged in discussion on present 'performance', when I am clearly betting on the future performance of this company. My stance on this subject is not unique, as the present performance of many of the technology companies does not necessarily justify present stock prices, however what does justify the price is where these companies may be going.

I initially invested in Sopheon following the PolyDoc name change, the press interest generated as a result of the change and following research into the company and the potential market in KM. My initial conclusion was that Sopheon would specialize only in the area of 'in-house' Knowledge Management, with a focus in the medical industry, despite some 'other industry' clients at that time.

I decided to invest on the basis of my assumption that Sopheon had (and has) 'perhaps' the potential to become one of the serious players within this specific market and the potential even within the 'limited' medical market was (and still remains) very good.
Within a handful of months I had recorded several hundred percentage points of profit and took the opportunity in early march to recoup my initial investment and a modest profit, retaining the majority of my stock. Various factors then coming together destroyed all confidence in tech stocks and wiped out the investments of later investors. Bearing similarities to the collapse of the UK Housing market in the late eighties and early nineties, where many 'overstretched' individuals lost considerable sums of money, and where everyone from the government & banks to individual real estate agents were blamed, quite simply one of the primary reasons to invest in any stock (gamble) is personal greed (which was the case with many of the property speculators in the late eighties and early nineties) and for those who had to 'cash in' at a loss, quite simply for them 'the horse lost'. I would also like to think that investors with the capability to 'hang around' for the long haul will not record losses unless they actually sell and for them (perhaps many on this board) the race has merely been delayed.

Since I initially invested, Sopheon has marketed across many diverse industries and list some substantial Companies and Government Agencies as clients/customers (these are all readily available on the Sopheon Website), and the Teltech merger will allow for even closer cooperation with their client base which by their own admission includes a large proportion of the Fortune 500. The below list (only the Sopheon client base) IMHO does not support the simplistic and unsupported statement by a regular bear poster to this board, that Sopheon 'is a pig of a company'.

FT.Com
Gruner and Jahr
FT Germany
Pearson group
Oxford University Press
Reuters
Public Record Office
MOD
BBC Monitoring
DERA
DTI
HM Customs and Excise
Home Office
Serious Fraud Office
DERA
British Telecom
BASF
Dunlop Aviation
DSM
SmithKline Beecham
Glaxo
Unilever
Program B.V.
Academisch Ziekenhuis Groningen
Academisch Ziekenhuis van de vrije Universiteit
Academisch Ziekenhuis Maastricht
In addition we also have solutions at over 50 Dutch hospitals

The focus for Sopheon/Teltech is diversifying with time, as stated earlier the initial information from the company pointed to medical and limited defense applications and solely for internal knowledge transfer. A 'trawl' through both companies marketing material and the Sopheon product range points clearly to external e-commerce solutions. This actually makes great sense, as one of the distinct 'failures' of the internet, company intranets and most 'complex' websites (with full search capability rather than merely links) is the relative inability of the system to separate 'the wheat from the chaff', or in many cases to come up with 'no matches', this situation is not good for businesses and especially ones moving more and more to e-commerce, as the potential to lose potential customers who cannot locate information on a service or product is great.

Bill Gates (though not God is a respected industry 'guru') has gone to great lengths in his book 'business @ the speed of thought' to point out that the next phase in the present development of the information age is the successful management of the information we are presently producing. Most companies today have merely replaced 'paper processes' with digital processes, with information primarily known to the individual author. Bill Gates sees internal networks and external portals developing into what he terms as a 'digital nervous system' and this 'next development' makes absolute sense, as we are not realizing the full benefit of the systems we presently have in place. To achieve the goal of 'digital nervous system' the products and support of companies like Sopheon/Teltech will be essential, as KM solutions will be at the heart of this system.

Has Sopheon got the correct product range and support structure to assist in this goal……..FT.com, Oxford University Press and Reuters (to name three) seem to think so, and I would place a degree of value on their decisions in the area of KM solutions.

[verwijderd] 16 oktober 2005 21:27

ging niet in 1x.

Assuming that the Sopheon software suite actually works (the client base appears to support this basic fact), then a read through the product range and functions performed by each solution or module is quite interesting, with a range of products providing an end to end solution (seemingly) for the control of documentation & information during the writing phase to the storage, management & retrieval of information at a later date.

A previous post argued that Sopheons products were merely a 'bolt on' to existing office tools and Sopheon for the most part 'merely' remarketed existing third party products. For most in business this is actually good news, as any hint that existing data would require a major 'format change' would be a costly deterrent to the implementation of such a system and the idea that present MS, Oracle or Lotus suites would be replaced by a non-standard suite would be a non-runner for most. Quite simple programs integrated with existing 'off-the-shelf' products to enhance their capability is nothing new, Business Objects being a simple example.

R&D budget was also an issue with a previous post, however from my understanding of how this type of business would operate (and reading the Teltech consultancy material), it would seem that most development would take place on an individual basis on location. Though more product orientated, the business (though diffirent in focus) does bear some similarities to the services offered by say PA Consulting in the way they are performed.

Notwithstanding the above however I would like to see some R&D (declared) spend going forward, as the basic products will obviously require adapting and upgrading to meet the requirements of new technology and to compete with alternative KM solutions.

Sopheon's success is by no means guaranteed, much will depend on the Management and penetration into key markets. Penetration into UK & European markets is quite evident from the Sopheon website and the Teltech deal will allow for even greater penetration of the US market, an extract from the Teltech website gives me sufficient confidence… 'Today, Teltech is the nation's leading independent provider of research and knowledge management consulting services to technology-driven companies. Our client base includes half the Fortune 500. Teltech has been recognized by Inc. Magazine as one of the nation's fastest-growing, privately held businesses.'

MS interest in the area of KM does not dampen my view, as MS is not noted for 'highly specialized tools', but rather seems to focus on small business and home business solutions, MS Access or MS Project being prime examples of 'good' products with limitations on database growth, with say Oracle and Primavera being possibly the larger users choice in such instances rather than the above MS products.

With brokers reportedly indicating a target for Sopheon in the region of £20, this part of the IT industry about to 'take off' IMO (and Bill Gates) combined with the Teltech merger makes this stock (which is back to it's early January level) worthy of consideration.

I could write more, be more specific or discuss other facts and issues regarding this company. However perhaps this post could be used as a kick off for a sensible discussion on KM and Sopheon's future position in this business.

[verwijderd] 16 oktober 2005 21:30

Voor degene die wat oudere berichten na willen kijken, het is echt wel de moeite waard om doormiddel van deze berichten de vorderingen van Sopheon in te schatten

www.sopheon.com/press.asp

vriendelijke groet lucas D

Noot:
Door op de links (rechts boven) te klikken verschijnt er nog meer informatie.

passeur 17 oktober 2005 01:08

Heb zelf ook een rijtje, zijn natuurlijk niet allemaal Accolade klanten maar ja, de Soof heeft meer te bieden,iemand nog aanvullingen of details?

1 Acist Medical Systems
2 ACH Food
3 Afton Chemical Corp
4 Airbus/Boeing
5 American Express
6 AMTEC
7 Atrium MC
8 AZM
9 Bady??????????
10 Basf
11 Bayer biological
12 Becton Dickinson
13 Berkshire Hathaway
14 Bristol-Myers Squibb
15 Cadbury Schweppes
16 Cargill
17 Celanese
18 Clariant
19 Clorox
20 Cytec surface (ubc)
21 Domtar
22 Dow chemical
23 DSM
24 Dupont
25 Ericsson
26 Eurest
27 Ferro
28 FH Brandenburg ?
29 FMC
30 Freudenberg
31 Fritolay
32 General Electric
33 Gerber
34 Glatfelter
35 GlaxoSmithKline
36 Great Lakes Chemical
37 Grohe
38 H.P.
39 Harley Davidson
40 Hospira
41 JM Huber
42 JM= Johns Manville
43 Lenzing AG
44 Lockheed Martin
45 Lonza
46 Lóreal
47 M.R.C.Z.
48 Mead Johnson
49 Merck/Biomet
50 Millipore
51 MobilOne
52 Monsanto
53 Mott
54 National archives
55 National Gypsum
56 Nautilus Group
57 Nestle
58 OCE
59 Pall Corp
60 Parker Hannifin
61 Pennzoil
62 Pfizer
63 Printpack
64 Reckitt Benckiser
65 Revlon
66 Sabic
67 Sanofi-Aventis
68 Sappi
69 Seagram
70 Shell
71 Siemens
72 Smith + Nephew
73 Stahl
74 Teijin Twaron
75 The Hartford
76 Ticona
77 Unifi inc
78 Vileda
79 Vodafone
80 Wellman
81 Whatman

Groet, Arno

passeur 17 oktober 2005 01:43

Voor de duidelijkheid nog een toevoeging bij gedaan, wie heeft er wat te melden?

1 Acist Medical Systems Accolade
2 ACH Food Accolade
3 Afton Chemical Corp Accolade
4 Airbus/Boeing SBS/Accolade
5 American Express Accolade
6 AMTEC Accolade
7 Atrium MC Accolade
8 AZM Accolade
9 Bady?????????? Accolade
10 Basf Accolade
11 Bayer biological Accolade
12 Becton Dickinson Accolade
13 Berkshire Hathaway Accolade
14 Bristol-Myers Squibb Accolade
15 Cadbury Schweppes Accolade
16 Cargill Accolade
17 Celanese Accolade
18 Clariant ?
19 Clorox ?
20 Cytec surface (ubc) Accolade
21 Domtar Accolade
22 Dow chemical ?
23 DSM ?
24 Dupont Accolade
25 Ericsson Accolade
26 Eurest Accolade
27 Ferro Accolade
28 FH Brandenburg Accolade
29 FMC ?
30 Freudenberg Accolade
31 Fritolay ?
32 General Electric CM
33 Gerber Reseller
34 Glatfelter Accolade
35 GlaxoSmithKline Accolade
36 Great Lakes Chemical Accolade
37 Grohe Accolade
38 H.P. ?
39 Harley Davidson ?
40 Hospira Accolade
41 JM Huber Accolade
42 Johns Manville Accolade
43 Lenzing AG Accolade
44 Lockheed Martin ?
45 Lonza Accolade
46 Lóreal ?
47 M.R.C.Z. Accolade
48 Mead Johnson Accolade
49 Merck/Biomet Accolade
50 Millipore Accolade
51 MobilOne Accolade
52 Monsanto ?
53 Mott Accolade
54 National archives CM
55 National Gypsum Accolade
56 Nautilus Group Accolade
57 Nestle ?
58 OCE ?
59 Pall Corp Accolade
60 Parker Hannifin Accolade
61 Pennzoil Accolade
62 Pfizer Accolade
63 Printpack Accolade
64 Reckitt Benckiser Accolade
65 Revlon Accolade
66 Sabic Accolade
67 Sanofi-Aventis Accolade
68 Sappi Accolade
69 Seagram Reseller
70 Shell Accolade
71 Siemens Reseller
72 Smith + Nephew ?
73 Stahl ?
74 Teijin Twaron Accolade
75 The Hartford ?
76 Ticona Accolade
77 Unifi inc Accolade
78 Vileda Accolade
79 Vodafone Accolade
80 Wellman Accolade
81 Whatman Accolade

[verwijderd] 17 oktober 2005 08:58

kopen kopen..niet kijken!
gr
j.

[verwijderd] 17 oktober 2005 09:02

FD.nl Publicatiedatum: 17-10-2005 08:30

Philips klopt marktprognoses in het derde kwartaal
Het elektronicaconcern Philips heeft in het derde kwartaal beter gepresteerd dan de markt vooraf had ingecalculeerd. Zowel de omzet- als de winstgroei overtrof de verwachtingen van de analisten.

De nettowinst kwam uit op euro 1,44 mrd, tegen euro 1,2 mrd over de vergelijkbare periode in 2004. Per aandeel steeg de winst van euro 0,92 naar euro 1,14. Marktvorsers rekenden gemiddeld op een winst van euro 1,2 mrd, of euro 0,98 per aandeel.

Tja, velen geloven dat ook deze klant is (geworden). Weten we nog? Innovatieplan!

[verwijderd] 17 oktober 2005 09:07

FD.nl
NPM Capital neemt HAK over van Heinz
AMSTERDAM (FD.nl/Betten) - NPM Capital neemt HAK over van H.J. Heinz Compay. Dat heeft de Nederlandse participatiemaatschappij vrijdagavond laat bekendgemaakt. Beide bedrijven verwachten binnen enkele weken overeenstemming te bereiken. Financiele details werden niet gegeven.

Ook Heinz wordt de laatste tijd als Accoladeklant genoemd. HAK zal geen Core business meer zijn!

Bertus S 17 oktober 2005 09:37

quote:
behoudend schreef:
HAK zal geen Core business meer zijn!

Yep, "doperwten met ketchup" verkocht totaal niet...............

Bertus S.

25 Posts, Pagina: 1 2 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 907,18 -2,33 -0,26% 11:16


Germany40^	23.147,30	+0,29%
BEL 20	4.421,55	-0,87%
Europe50^	5.474,66	-0,26%
US30^	42.680,80	-0,74%
Nasd100^	20.379,10	-1,15%
US500^	5.787,00	-0,97%
Japan225^	37.249,00	-1,18%
Gold spot	2.895,31	-0,81%
EUR/USD	1,0787	-0,04%
WTI	66,55	+0,21%